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Crusted (Norwegian) scabies is a severe and highly 
contagious form of infestation caused by the mite Sarcoptes 
scabiei var. hominis. It occurs in a subgroup of patients who 
are either immunocompromised or physically or mentally 
debilitated. Due to its atypical clinical presentation as well 
as difficulties associated with its management it presents a 
number of challenges both from a therapeutic aspect as well 
as from public health perspective. Failure to diagnose this 
condition may give rise to a massive epidemic when the 
patient is in an institutional setting.  
We describe a case of crusted scabies which occurred 
in a nursing home leading to an institutional outbreak. She 
received a combination of oral ivermectin and topical 
scabicidal with good results. 
This case highlights the importance of being alert to 
the possible diagnosis of crusted scabies and gives an 






























Scabies is an inflammatory disease of the skin caused 
by the burrowing mite Sarcoptes scabiei var. hominis. It is 
a common worldwide problem affecting as many as 300 
million people worldwide annually.1-2 Data collected by the 
Royal Infirmary of Edinburgh from 1815 to 2000 indicate 
a prevalence of about 5%, with rising incidence and 
prevalence during war-time.3  In a recent study carried out 
in the UK, the mean prevalence was 2.27 in 1000 for boys 
and men and 2.81 in 1000 for girls and women.4 It occurs 
in all age groups, races and socio-economic groups, 
although institutionalization, poverty, poor hygiene, 
overcrowding, undernourishment and sexual promiscuity 
have been proposed as significant risk factors.4 It has a 
history as long as mankind as has been described by 
Aristotle (384 BC – 322 BC) and in the Old Testament. 
Crusted scabies was originally called Norwegian 
scabies because the condition was first described in 
Norway in 1848 among patients with leprosy.5 In fact, it 
may occur in any subject who is immunocompromised, 
malnourished, debilitated or has sensory impairment. 
 
Case Report 
A 92-year-old lady, resident in a home for the elderly, 
was admitted to Mater Dei Hospital because of an elevated 
INR greater than 10. On examination by the admitting firm 
she was noted to have a widespread, excoriated scaly 
eruption.  
The patient had been bed-bound for several years and 
suffered from dementia and longstanding paresis, due to 
cerebrovascular disease. She was on long term bumetanide, 
warfarin, perindopril and iron supplements (Ferroglobin). 
Direct history taking was not possible because of her 
mental state. According to her carers the patient had had 
increasing skin scaling for several months, initially on the 
hands and scalp, gradually becoming more widespread. For 
some time she had been treated with topical steroid creams 
for presumed psoriasis with no improvement; more 
recently generalised erythema had appeared.   
On examination there were large areas of warty 
crusting on the hands, feet and scalp with thickening and 
fissuring of the palms and soles (Figs 1,2). The fingernails 
were thickened and discoloured with scaly debris evident 
in the distal subungual spaces. In addition, there was 
generalised erythema with widespread excoriated papules, 
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particularly over the breasts, axillae and abdomen. No 
typical scabetic burrows were identified. The patient was 
visibly uncomfortable and constantly attempting to scratch 
her skin, although she was unable to do so effectively 
because of her neurological state and flexural contractures. 
A clinical diagnosis of crusted (Norwegian) scabies 
was made and one application of 0.5% malathion lotion 
(Derbac-M®) applied. In view of the extent and severity of 
skin involvement a decision was made to transfer the 
patient to the Dermatology ward at Sir Paul Boffa Hospital 
for further management. She was treated systemically with 
oral ivermectin (Stromectol) 6 mg (equivalent to 
200µg/kg). She was simultaneously treated topically with 2 
applications of 5% permethrin cream (Lyclear® dermal 
cream) applied, 3 days apart, to all the skin surface, 
including the scalp, and left on for 12 hours. She was also 
given a one-week course of oral flucloxacillin in view of 
the generalised erythema thought likely to be secondary to 
staphylococcal skin sepsis. The patient was nursed in a 
single room and members of staff who came in contact with 
her were instructed to wear gloves and long-sleeved gowns 
to avoid infection. The fingernails were trimmed and 
subungual debris removed. The generalised erythema 
subsided within a few days. However, since after 1 week 
significant crusting was still present, especially on the 
palms and scalp, the patient was retreated with oral 
ivermectin 6 mg (2 doses 2 days apart) and a further 
application of permethrin cream. The skin eventually 
cleared completely and she was discharged back to her 
nursing home 2 weeks after admission. She remained clear 
when reviewed at the home 6 weeks later. 
The case was notified to the Public Health 
Department. It transpired that other cases of scabies in 
residents of the same home had recently been reported. The 
home was visited by public health physicians and a 
dermatologist (MJB) and all residents, staff and contacts 
were treated. Ivermectin was prescribed to the most 
severely affected cases. 
 
Discussion 
Crusted scabies is a clinically distinct and highly 
contagious form of scabies. It presents several clinical 
challenges including diagnostic and therapeutic ones as 
well as posing a particular public health problem. Crusted 
scabies occurs when the host’s response to the mite is 
altered or inadequate (Table 1). It may occur in 
immunosuppression due to disease such as HIV or 
lymphoproliferative disorders as well as iatrogenic causes 
including post-transplant patients and those on drugs which 
modify the immune response such as long-term 
corticosteroids. Given its increased use in dermatology, 
rheumatology and gastroenterology it is pertinent to note 
that there has been a report of a case of scabies occurring 
during treatment with infliximab.6 Inappropriate use of 
potent topical steroids may predispose to this condition as 
well. In addition it may develop in the context of severe 
systemic illness or when there is neurological disease 
which either causes immobility and a reduced ability to 
scratch and thus dislodge the mites or gives rise to reduced 
sensation.  
 
Table 1: Factors predisposing to crusted scabies 
 
In these patients there is a reduced reaction to the mite 
due to failure of the skin immune system to mount an 
effective response. It has been reported that in such cases 
there is a predominance of infiltrating CD8+ T 
lymphocytes in the dermis with minimal helper T 
lymphocytes (CD4+) and an absence of any B cells.7 There 
may also be a reduced physical response to the mite (i.e. 
diminished scratching) or both these factors working in 
tandem. This results in absent or diminished symptoms 
(only about 50% of patients with crusted scabies have an 
itch) as well as giving rise to atypical and exaggerated 
clinical signs.  
Due to the altered host response to the mite, the 
clinical presentation differs considerably and this may give 
rise to difficulty in diagnosis with resultant delay in proper 
treatment. In cases where the patient lives in an institution 
this poses a public health risk as this form of scabies is 
highly contagious due to the fact that there may be 
hundreds of thousands of mites present on the host, whereas 
there are usually only 10-20 females in classical scabies.8 
Such patients shed large amounts of scale which contain 
vast quantities of mites. 
  Crusted scabies presents as a hyperkeratotic eruption 
particularly marked on the palms and soles which may be 
 
 Immunosuppression 
o Post-transplant patients 
o HIV/AIDS, HTLV-1 
o Leukaemia, lymphoma 
o Drugs e.g. corticosteroids, immune 
modulators 
 
 Severe systemic disease 
o Rheumatoid arthritis or other severe 
arthropathy 
o Systemic lupus erythematosus 
o Epidermolysis bullosa 
 
 Neurological disease 
o Paresis 
o Dementia 
o Mental illness 
o Down’s syndrome 
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fissured and/or warty. This may be accompanied by 
erythema and scaling on the face, neck, scalp and trunk 
which may become generalized. There is frequently an 
accumulation of scaly debris under the nails. It occasionally 
presents as erythroderma as in this case. Staphylococcus 
aureus colonizing burrows might play a part in initiating 
the erythroderma.9 Secondary infection may also occur 
with other organisms, commonly Streptococcus pyogenes 
and this leads to increased mortality in this subgroup of 
patients.10 Patients may also have generalised 
lymphadenopathy and frequently exhibit eosinophilia and 
elevated total IgG and extremely elevated IgE levels (up to 
ten times normal levels).7 
As it mimics other common dermatoses such as 
psoriasis, eczema and contact dermatitis the diagnosis of 
scabies should always be kept in mind particularly when 
examining patients in the at-risk categories who, in 
addition, may be unable to give a proper history. It is 
frequently misdiagnosed as “senile pruritus” by primary 
caregivers and is treated with topical corticosteroids which 




Crusted scabies presents a treatment challenge for 
several reasons. The huge burden of infestation usually 
requires several treatments and relapse is common. 
Although treatment with a combination of topical and oral 
treatment is generally recommended11-12 the presence of a 
compromised skin barrier function may lead to a greater 
risk of toxicity through increased skin absorption. In 
addition local side-effects such as skin irritation and a 
burning sensation may be exacerbated in this situation. 
The Centers for Disease Control and Prevention 
(CDC) currently recommends combined treatment with a 
topical scabicide and repeated treatment with oral 
ivermectin 200μg/kg on days 1, 2, 8, 9, and 15. Additional 
treatment on days 22 and 29 might be required for severe 
cases. Ivermectin should be combined with the application 
of either 5% topical benzyl benzoate or 5% topical 
permethrin (full body application to be repeated daily for 7 
days then 2 times weekly until release from care or cure).11 
This is in contrast to classical scabies which usually only 
requires 2 applications, one week apart, of a topical 
scabicide. 
Ivermectin binds selectively to receptors in the 
peripheral motor synapses of the mite, blocking chemical 
transmission of g-aminobutyric acid (GABA)-gated 
chloride channels localized in the CNS. This stimulates the 
discharge of GABA at the nerve endings of endoparasites, 
increasing the affinity of GABA in the receptor at synapses 
and causing interruption of the nerve impulses, producing 
paralysis and death of parasites.13 Ivermectin is relatively 
safe. Reported adverse reactions include fever, headache,  
chills, arthralgia, rash, eosinophilia, and anorexia. 
However, many of these symptoms are thought to result 
from the death of parasites rather than as a reaction to the 
drug.14 
There are several advantages to using oral ivermectin 
over standard topical scabicides.15 These include high 
efficacy, ease and rapidity of application and avoiding the 
irritation caused by topical treatments.  It also mitigates to 
some extent for improper/inadequate application of topical 
agents (this may apply in particular to institutional 
outbreaks where staff may have to deal with many cases 
concurrently). It is thus convenient for persons who are 
bedridden and immunocompromised. 
In crusted scabies, topical scabicides should be applied 
from head to toe including the scalp, face, ears and flexures 
and left in contact with the skin for the recommended 
amount of time (usually 12 hours for permethrin and 24 
hours for malathion). Several treatments are usually 
needed. Special attention should be paid to the nails as they 
are frequently a haven for mites and thus a source of 
recurrence/treatment failure. Nails should thus be clipped 
short and any subungual debris removed. Topical agents 
should then be applied to the subungual space and nailfolds. 
Secondary bacterial infection should be treated with 
appropriate antibiotics as this is a major cause of morbidity 
and even mortality. 
Since topical treatments tend to cause irritation and 
xerosis of the skin they should be followed by the liberal 
use of emollients. A sedating antihistamine may be 
necessary for a few days to control the itching and allow for 
undisturbed sleep. 
 
Other control measures 
In cases where an institution is involved, 
environmental control measures should include patient 
isolation until therapy is completed, barrier precautions 
with long-sleeved gowns and gloves, and screening and 
synchronous treatment of infected caregivers and close 
contacts. Visitors should be limited to reduce opportunity 
for spread.  
The bedding and clothing used by a person with 
crusted scabies should be collected and transported in a 
plastic bag and emptied directly into washer to avoid 
contaminating other surfaces and items; all items should be 
machine-washed and dried using hot water and high heat 
cycles (temperatures in excess of 50°C for 10 minutes will 
kill mites and eggs); laundry personnel should use 
protective garments and gloves when handling 
contaminated items. Items that cannot be washed should be 
sealed in a plastic bag for 72 hours.12 
Public health officials should be involved as soon as 
the diagnosis is made to guide the institution regarding best 
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and make sure all contacts are traced and treated. 
Moreover, when the patient has been harbouring the 
infestation for many months (as in this case) it is essential 
to trace any staff that may have left for another job in the 
meantime. This is important both for the individuals 
involved as well as to avoid transfer of the infestation to 
other institutions. Similarly, this should also be applied to 
any residents that may have recently left the facility. 
 
Conclusion 
Crusted scabies is a distinct form of scabies affecting 
patients who are debilitated and it is a severe form of 
infestation with the mite Sarcoptes scabiei var. hominis. It 
often poses a challenge as it is frequently misdiagnosed for 
other dermatoses. Once diagnosed there are also pitfalls in 
the treatment due to the number of organisms present as 
well as to general conditions affecting this subgroup of 
patients.  A combination of topical and systemic treatment 
is necessary for adequate control and this must be 
accompanied by public health measures. This case clearly 
demonstrates the consequences of a delay in diagnosis as 
well as the highly contagious nature of crusted scabies as it 
resulted in a large outbreak affecting many of the residents 
as well as members of staff and took several months to be 
completely eradicated. It is therefore very important for 
healthcare staff to be aware of the possibility of such a 
diagnosis and maintain a high index of suspicion, if 
necessary referring early for specialist dermatological 
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